| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/BBRC.1999.0683 |
| P698 | PubMed publication ID | 10329429 |
| P2093 | author name string | Hirano T | |
| Ono K | |||
| Tsuchiya M | |||
| Yoshimura Y | |||
| Kawai S | |||
| Ozaki S | |||
| Ozaki Y | |||
| Koishihara Y | |||
| Kosaka M | |||
| Ohtomo T | |||
| Sugamata Y | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| multiple myeloma | Q467635 | ||
| P304 | page(s) | 583-591 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells | |
| P478 | volume | 258 |
| Q24319113 | A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells |
| Q54976472 | A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses. |
| Q73668163 | A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta |
| Q40596850 | A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells |
| Q28384647 | Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells |
| Q33358934 | Altered gene expression in highly purified enterocytes from patients with active coeliac disease |
| Q39801517 | Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein |
| Q35531194 | Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells |
| Q84994578 | Antigen-Dependent Internalization Is Related to Rapid Elimination from Plasma of Humanized Anti-HM1.24 Monoclonal Antibody |
| Q33807551 | Antiviral activity of the interferon-induced cellular protein BST-2/tetherin |
| Q34311435 | Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection |
| Q34905536 | BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action |
| Q24630382 | BST-2/tetherin: a new component of the innate immune response to enveloped viruses |
| Q36064594 | BST2 Mediates Osteoblast Differentiation via the BMP2 Signaling Pathway in Human Alveolar-Derived Bone Marrow Stromal Cells |
| Q26774878 | Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses |
| Q38825662 | Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study |
| Q28580409 | Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology |
| Q35562726 | C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif |
| Q33528976 | CAML does not modulate tetherin-mediated restriction of HIV-1 particle release |
| Q35405550 | CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia |
| Q34325965 | CD317/tetherin is an organiser of membrane microdomains |
| Q51888826 | Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. |
| Q33867470 | Cloning and characterization of the antiviral activity of feline Tetherin/BST-2 |
| Q28537997 | Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors |
| Q37242499 | Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species |
| Q28659945 | Counteraction of the multifunctional restriction factor tetherin |
| Q35665926 | Dendritic cell-based immunotherapy in multiple myeloma |
| Q34416492 | Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein |
| Q24629504 | Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin |
| Q35848677 | Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. |
| Q37638965 | Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence |
| Q33501744 | Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses |
| Q27316022 | Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles |
| Q40359568 | Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal |
| Q39614822 | Ebolavirus Replication and Tetherin/BST-2. |
| Q38326209 | Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. |
| Q35076983 | Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection |
| Q36086707 | Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein |
| Q37336745 | Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions |
| Q37384691 | HIV-1 Vpu - an ion channel in search of a job. |
| Q39536992 | HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction |
| Q24619066 | HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms |
| Q24646984 | HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes |
| Q37257389 | HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin |
| Q28595739 | HSV-2 glycoprotein gD targets the CC domain of tetherin and promotes tetherin degradation via lysosomal pathway |
| Q47230024 | High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release |
| Q37252004 | Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches |
| Q36548179 | Host restriction factors in retroviral infection: promises in virus-host interaction |
| Q38813353 | Human parainfluenza virus type 2 V protein inhibits induction of tetherin |
| Q38166716 | Human plasmacytoid dendritic cells: from molecules to intercellular communication network |
| Q39629094 | IFN-γ-induced BST2 mediates monocyte adhesion to human endothelial cells |
| Q36463634 | IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. |
| Q31086787 | Identification and functional analysis of three isoforms of bovine BST-2 |
| Q35028829 | Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach |
| Q34426491 | Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities |
| Q35170879 | In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans |
| Q36270509 | Increased BST2 expression during simian immunodeficiency virus infection is not a determinant of disease progression in rhesus monkeys |
| Q24652263 | Inhibition of Lassa and Marburg virus production by tetherin |
| Q28585561 | Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons |
| Q92703239 | Interplay between Intrinsic and Innate Immunity during HIV Infection |
| Q33826655 | Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses |
| Q41851826 | Involvement of a Golgi-resident GPI-anchored protein in maintenance of the Golgi structure |
| Q24302300 | Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways |
| Q59354447 | Limiting Respiratory Viral Infection by Targeting Antiviral and Immunological Functions of BST-2/Tetherin: Knowledge and Gaps |
| Q28534707 | Mechanism of HIV-1 virion entrapment by tetherin |
| Q37658537 | Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo |
| Q24650331 | Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus |
| Q34645914 | Molecular mechanism of arenavirus assembly and budding |
| Q38090691 | Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma |
| Q38050507 | Monoclonal antibody-based immunotherapy for multiple myeloma |
| Q33450556 | Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion |
| Q36637651 | NY-ESO-1 immunotherapy for multiple myeloma |
| Q33822677 | Novel immunotherapies |
| Q43433320 | Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin |
| Q39325995 | Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. |
| Q30369981 | Positioning of cysteine residues within the N-terminal portion of the BST-2/tetherin ectodomain is important for functional dimerization of BST-2. |
| Q37132866 | Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function |
| Q33269787 | Quantitative membrane proteomics reveals new cellular targets of viral immune modulators |
| Q24309134 | Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction |
| Q42234287 | Restriction of Retroviral Replication by Tetherin/BST-2. |
| Q37069802 | Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. |
| Q35383228 | Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin |
| Q36281167 | Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference |
| Q61816755 | Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration |
| Q34055580 | Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells |
| Q40644713 | Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage |
| Q35607295 | Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism |
| Q27665937 | Structural and Biophysical Analysis of BST-2/Tetherin Ectodomains Reveals an Evolutionary Conserved Design to Inhibit Virus Release |
| Q27664759 | Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations |
| Q24306855 | Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain |
| Q47155329 | Structural determinant of BST-2-mediated regulation of breast cancer cell motility: a role for cytoplasmic tail tyrosine residues |
| Q38568867 | Surveillance of cell and tissue perturbation by receptors in the LRC. |
| Q97420794 | Targeted Therapy With Immunoconjugates for Multiple Myeloma |
| Q27026161 | Targeted therapy for HM1.24 (CD317) on multiple myeloma cells |
| Q57133171 | Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation |
| Q37827428 | Tetherin and its viral antagonists |
| Q34019962 | Tetherin inhibits HIV-1 release by directly tethering virions to cells |
| Q35038590 | Tetherin inhibits prototypic foamy virus release |
| Q38933327 | Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins |
| Q33564429 | The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin |
| Q41762850 | The cytosolic N-terminus of CD317/tetherin is a membrane microdomain exclusion motif. |
| Q35115811 | The expression of BST2 in human and experimental mouse brain tumors. |
| Q21245050 | The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu |
| Q21090506 | The great escape: viral strategies to counter BST-2/tetherin |
| Q34492477 | The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? |
| Q26752737 | The role of BST-2/Tetherin in host protection and disease manifestation |
| Q34664616 | The role of BST2/tetherin in feline retrovirus infection |
| Q36492793 | The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release |
| Q41984737 | The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. |
| Q28251869 | Transcription factor GATA-1 and Down syndrome leukemogenesis |
| Q31034125 | Ultra structural characterisation of tetherin - a protein capable of preventing viral release from the plasma membrane |
| Q37303172 | Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach |
| Q33425484 | Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis |
| Q35275193 | Upregulation of BST-2/Tetherin by HIV infection in vivo |
| Q35826825 | Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling |
| Q33455505 | Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking |
| Q24644811 | Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism |
| Q37115275 | Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion |
| Q84561051 | Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation |
Search more.